摘要
目的通过对肾移植术后患者肝功损害的原因分析,总结乙肝病毒对肾移植受体肝脏的损害及治疗措施。方法根据乙肝标志物将患者分为三组:A组(HBsAg+、HBeAg+和HBV-DNA+),B组(HBsAg+、HBeAg-和HBV-DNA-),C组(HbsAg-、HBeAg-和HBV-DNA-),对其肾移植术后肝功情况进行分析,对不同原因的肝损害采用调整免疫抑制剂量或加用保肝药物并观察效果。结果A组肝损害发生率41.9%,与C组比较差异有显著性;B组肝损害发生率22.6%,与C组比较差异无显著性。结论肾移植术后药物性肝损害出现在3个月内,而病毒性肝损害以6个月到2年为多见。合并乙肝病毒感染的肾移植患者更易发生肝损害,通过保肝以及加用拉米夫定使肝功恢复正常。
[Objective] To analyze cause of the liver damage after renal transplantation, and to summarize the therapy of the liver damage in hepatic virus. [Methods] Based on the markers of Hepatitis B, patients were divided into three groups： Group A （HBsAg＋, HBeAg＋, HBV-DNA＋）, group B （HBsAg＋, HBeAg-, HBV-DNA-）, group C （HbsAg-, HBeAg-, HBV-DNA-）, then the liver damage after renal transplantation was analyzed. Different treatment was undertaken on different group patients. And the outcome was analyzed. [Results] The incidence of liver damage in group A is 41.9%, and there is significant difference compared with group C. The incidence in group B is 22.6%, and there is no significant difference compared with group C. [Conclusions] Drug-oriented liver damage occurred mostly in three months after transplantation, while Hepatitis-oriented occurred mostly between six months and two years. It is liable to emerge liver damage in Hepatitis B patient after transplantation, and liver function return to norreal through adding Lamivudine or conservative Hepar medicine.
出处
《中国现代医学杂志》
CAS
CSCD
北大核心
2007年第5期580-582,共3页
China Journal of Modern Medicine
关键词
肾移植
肝损害
乙肝病毒
免疫抑制剂
renal transplantation
liver damage
Hepatitis B
immunosuppressant
